Pharmacokinetics of new oral hepatitis C antiviral drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 1, 2013, Pages 5-16

  Vispo, Eugenia ^a   Barreiro, Pablo ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

DAA; DDI; Drug drug interactions; Hepatitis C; HIV; Pharmacokinetics

Indexed keywords

ABT 072; ABT 267; ABT 333; ABT 450; ACH 1625; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ASUNAPREVIR; AZD 7925; BI 207127; BMS 791325; BMS 824393; CARBOXYLIC ACID; CF 102; CILUPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; GS 9256; GS 938; GS 9451; IDX 184; IMMUNOSUPPRESSIVE AGENT; INX 189; LOMIBUVIR; MERICITABINE; MK 5172; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROTEINASE INHIBITOR; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDE; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VX 759;

ANTIVIRAL ACTIVITY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; GENOTYPE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 84871190914     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.729577     Document Type: Review

References (70)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
2. Hadziyannis S, Sette H, Morgan T, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med 2004;140:346-55
3. McHutchison J, Lawitz E, Shiffman M, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
4. Lamarre D, Anderson P, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9 (Pubitemid 37442587)
5. Lin C, Kwong A, Perni R. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3-16 (Pubitemid 43796632)
6. Perni R, Almquist S, Byrn R, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909 (Pubitemid 43327793)
7. Lin K, Perni R, Kwong A, Lin C. VX- 950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006;50:1813-22
8. Reesink H, Zeuzem S, Weegink C, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002 (Pubitemid 44498690)
9. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or
10. hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68
11. Van Heeswijk R, Boogaerts G, Garg V, et al. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. Abstracts of the6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 23 - 24 June 2010; Boston, MA, USA
12. Van Heeswijk R, Boogaerts G, De Backer K, et al. The pharmacokinetic interaction between esomeprazole and the investigational HCV protease inhibitor telaprevir [abstract 11]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 23 - 24 June 2010; Boston, MA, USA
13. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir [abstract PK13]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22 - 23 June 2011; Cambridge, MA, USA
14. Garg V, van Heeswijk R, Yang Y, et al. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol 2011;In press
15. Luo X, van Heeswijk R, Alves K, et al. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK11]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22 - 23 June 2011; Cambridge, MA, USA
16. Garg V, Chandorkar G, Farmer H, et al. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2011;In press
17. Lee J, van Heeswijk R, Alves K, et al. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011;55:4569-74
18. Garg V, van Heeswijk R, Lee J, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7
19. Van Heeswijk R, Vandevoorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 1244. J Hepatol 2011;54(Suppl 1):S491
20. Chakilam A, Chavan A, Smith G, et al. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin [abstract PK20]. Abstracts of the 6th International Workshop on Clinical Pharmacology of
21. Hepatitis Therapy; 22 - 23 June 2011; Cambridge, USA
22. Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011;6:514-26
23. Van Heeswijk R, Vandevoorde A, Boogaerts A, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract 119]. Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February - 2 March 2011; Boston, USA
24. Sulkowski M, Dieterich D, Sherman K, et al. New HIV and HCV antiviral agents, prevention, and ARV strategies [abstract 146LB]. Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February - 2 March 2011; Boston, USA
25. Kakuda T, Leopold L, Nijs S, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial [abstract 018]. Abstracts of the 13th Intl Workshop on Clinical Pharmacology of HIV Therapy; 16 - 18 April 2012; Barcelona, Spain
26. Van Heeswijk R, Boogaerts G, Vandevoorde A, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers [abstract LB A1-1738]. Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 - 20 September 2011; Chicago, IL, USA
27. Malcolm B, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease,suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-20 (Pubitemid 43327807)
28. Victrelis1 (Boceprevir) US Prescribing Information, FDA. Available from: http://www.merck. com/product/usa/ pi-circulars/v/victrelis/victrelis-pi.pdf [Accessed 3 May 2012]
29. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8 (Pubitemid 46627577)
30. Kaserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion and drug-drug interactions [abstract 118]. Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February - 2 March 2011; Boston, USA
31. Hammond K, Wolfe P, Burton J, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers [abstract 015]. Abstracts of the13th Intl Workshop on Clinical Pharmacology of HIV Therapy; 16 - 18 April 2012; Barcelona, Spain
32. Hulskotte E, Feng H, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir and darunavir [abstract 771LB]. Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5 - 8 March 2012; Seattle, USA
33. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results. Abstracts of the 47th EASL Annual Meeting; Barcelona, 2012; Abstract 50. J Hepatol 2012;56(Suppl 2):22
34. de Kanter C, Blonk M, Colbers A, et al. The influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir [abstract 772LB]. Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5 - 8 March 2012; Seattle, USA
35. Reesink H, Fanning G, Farha K, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis N patients. Gastroenterology 2010;138:913-21
36. Lin T, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009;53:1377-85
37. Fried M, Buti M, Dore G, et al. Efficacy and safety of TMC 435 in combinationwith peginterferon-2a and ribavirin in treatment-naive genotype-1 HCV patients: 24 week interim results from de PILLAR study. Hepatology 2010;52(Suppl 1):LB-5
38. Moreno C, Berg T, Tanwandee T, et al. A phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6 [abstract 895]. Abstracts of the 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29 - November 2 2010; Boston, USA
39. Sekar V, Simion A, Peeters M, et al. Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 472. J Hepatol 2011;54(Suppl 1):193
40. Beaumont-Mauviel M, Simion A, De Smedt G, et al. The pharmacokinetic interaction between the investigational HCV NS3/4A protease inhibitor TMC435 and escitalopram [abstract 1354]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 4 - 8 November 2011; San Francisco, USA
41. Beaumont-Mauviel M, De Smedt G, Peeters M, et al. The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone [abstract 1353]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 4 - 8 November 2011; San Francisco, USA
42. Ouwerkerk-Mahadevann S, Sekar V, Peeters M, et al. The pharmacokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers [abstract 49]. Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5 - 8 March 2012; Seattle, USA
43. White P, Llinas-Brunet M, Amad M, et al. Preclinical characterization of BI-201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010;54:4611-18
44. Manns M, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54:1114-22
45. Sulkowski M, Ceasu E, Asselah T, et al. SILEN-C1: sustained virologic response and safety of BI-201335 combined with peginterferon a-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV infection. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 60. J Hepatol 2011;54(Suppl 1):27
46. Sulkowski M, Bourliere M, Bronowicki J, et al. SILEN-C2: sustained virologic response and safety of BI-201335 combined with peginterferon a-2a and ribavirin (P/R) in chronic HCV genotype 1 patients with non-response to P/R. In: abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 66. J Hepatol 2011. 54(Suppl 1): 30
47. Soriano V, Gane E, Angus P, et al. The efficacy and safety of the interferon-free combination of BI201335 and BI207127 in genotype 1 HCV patients with cirrhosis - interim analysis from SOUND-C2 [abstract 1420]. 47th EASL; 18 - 22 April 2012; Barcelona
48. Sane R, Podila L, Mathur A, et al. Mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCV NS3/4A protease inhibitor BI- 201335. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 1236. J Hepatol 2011. 54(Suppl 1):488
49. Bressanelli S, Tomei L, Rey F, et al. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 2002;76:3482-92 (Pubitemid 34224549)
50. Lee J, Nam I, Myung H. Nonstructural protein 5B of hepatitis C virus. Mol Cells 2006;21:330-6 (Pubitemid 44027680)
51. Gane E, Stedman C, Hyland R, et al. PSI-7977: ELECTRON. Interferon is not required for sustained virologic response in treatment-naive patients with HCV GT2 or GT3 [abstract 34]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 - 8 November 2011; San Francisco, California
52. Lawitz E, Lalezari J, Hassanein T, et al. PROTON: PSI-7977 and pegIFN/RBV in treatment-naive patients with HCV GT1: sustained virologic response [abstract 225]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 - 8 November 2011; San Francisco, California
53. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus pegIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 61. J Hepatol 2011;54(Suppl 1):28
54. Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. Abstracts of the 47th EASL Annual Meeting, Barcelona, 2012. Abstract 1101. J Hepatol 2012;56(Suppl 2):S433
55. Denning J, Cornpropst M, Clenons D, et al. Lack of effect of the nucleotide analog PSI-7977 an methadone pharmacokinetics and pharmacodynamics [abstract 372]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 - 8 November 2011; San Francisco, California
56. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-coinfected patients. AIDS 2011;25:2197-208
57. Soriano V, Vispo E, Barreiro P. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. AIDS 2011;25:1013-14
58. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13:429-37 (Pubitemid 352016736)
59. Gao M, Nettles R, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100
60. Qiu D, Lemm J, O'Boyle D, et al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol 2011;92:2502-11
61. Fridell R, Qiu D, Valera L, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011;85:7312-20
62. Nettles R, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54:1956-65
63. Bifano M, Sevinsky H, Persson A, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) insubjects with hepatic impairment compared with healthy subjects [abstract 1362]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 - 8 November 2011; San Francisco, California
64. Pol S, Ghalib R, Rustgi VK, et al. High rates of SVR24 for BMS-790052, a NS5A replication complex inhibitor, in combination with Peg-IFNa-2A and ribavirin: phase 2a trial in treatment naive HCV-genotype 1 subjects [abstract H1-376]. Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 - 20 September; Chicago, IL, USA; 2011
65. Hezode C, Hirschfield G, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results [abstract 227].
66. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/-ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. Abstracts of the 47th EASL Annual Meeting, Barcelona, 2012. Abstract 1422. J Hepatol 2012. 56(Suppl 2):560
67. Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/ intolerant to peginterferon. Abstracts of the 47th EASL Annual Meeting, Barcelona, 2012. Abstract 14. J Hepatol 2012. 56(Suppl 2): 7
68. Lok A, Gardiner D, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24
69. Bifano M, Sevinsky H, Persson A, et al. Daclatasvir (DCV; BMS-790052) has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects [abstract 1340]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 - 8 November 2011; San Francisco, California
70. Bifano C, Hwang C, Oosterhuis B, et al. Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile that supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir [abstract 618]. Abstracts of 19th Conference on Retroviruses and Opportunistic Infections; 5 - 8 March 2012; Seattle